335200-36-7Relevant academic research and scientific papers
Nitroxide derivative of ROCK kinase inhibitor
-
, (2020/06/17)
The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.
SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
-
Paragraph 0150, (2019/02/28)
To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising
MATRIX METALLOPROTEINASE INHIBITORS
-
Page/Page column 26, (2008/06/13)
Compounds of Formula (I), wherein R1 represents optionally substituted -C4-12 alkyl, -C2-10alkylcycloalkyl, -C2-6 alkyl heterocycloalkyl, -C2-6alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl, except pyridinyl. Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR3; R2 represents CONH2, CO2H, CO2R7, SO2R7 or SO2NR8R9, except that R2; may not represent CO2R7 when X is CONH2 ; R3 represents OR6, or NR8R9; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 represents H or C1-6 alkyl; R7 represents C1-6 alkyl; R8 and R9 each independently represents H or C1-6 alkyl or R8 and R9 together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; and physiologically functional derivatives thereof with the exception of [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; butanedioic acid [4-(phenylmethoxy)phenyl]; with the proviso that when R1 represents C4-12 alkyl, Z is other than a bond, O or CH2; and physiologically functional derivatives thereof , processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.
Solid-phase synthesis of oligoesters using a JandaJel resin
Brümmer, Oliver,Clapham, Bruce,Janda, Kim D.
, p. 2257 - 2259 (2007/10/03)
This communication describes a general method for the solid-phase synthesis of oligomeric esters. A JandaJel resin was utilized as the solid support in conjunction with the highly acid labile Rink linker. Ester coupling reactions were performed using buff
Antibody-catalyzed hydrolysis of oligomeric esters: A model for the degradation of polymeric materials
Bruemmer,Hoffman,Chen,Janda
, p. 19 - 20 (2007/10/03)
A catalytic antibody has been discovered that degrades oligomeric ester substrates.
